Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. (19th July 2016)

• Record Type: Journal Article
• Authors: Saslow, Debbie; Andrews, Kimberly S.; Manassaram‐Baptiste, Deana; Loomer, Lacey; Lam, Kristina E.; Fisher‐Borne, Marcie; Smith, Robert A.; Fontham, Elizabeth T. H.
• Is Part Of: CA. Volume 66:Number 5(2016:Sep./Oct.)
• Page Start: 375
• Page End: 385
• Publication Date: 2016-07-19
• Subjects: American Cancer Society -- Advisory Committee on Immunization Practices -- guideline -- human papillomavirus (HPV) -- vaccine -- cancer prevention; Cancer -- Periodicals; Neoplasms -- Periodicals; Neoplasms; 616.99405
• DOI: 10.3322/caac.21355
• Languages: English
• ISSNs: 0007-9235

Abstract

Abstract: Answer questions and earn CME/CNE The American Cancer Society (ACS) reviewed and updated its guideline on human papillomavirus (HPV) vaccination based on a methodologic and content review of the Advisory Committee on Immunization Practices (ACIP) HPV vaccination recommendations. A literature review was performed to supplement the evidence considered by the ACIP and to address new vaccine formulations and recommendations as well as new data on population outcomes since publication of the 2007 ACS guideline. The ACS Guideline Development Group determined that the evidence supports ACS endorsement of the ACIP recommendations, with one qualifying statement related to late vaccination. The ACS recommends vaccination of all children at ages 11 and 12 years to protect against HPV infections that lead to several cancers and precancers. Late vaccination for those not vaccinated at the recommended ages should be completed as soon as possible, and individuals should be informed that vaccination may not be effective at older ages.CA Cancer J Clin 2016;66:375–385. © 2016 American Cancer Society.